By Nana O 
Scientists at the University of Cambridge have created miniature, lab-grown brain and spinal cord systems that precisely mimic the intricate pathways of movement signals within the human nervous system. This remarkable scientific achievement has yielded a paradigm-shifting discovery: nerve damage, long considered irreversible, may indeed be amenable to regeneration under specific conditions. The research, published in the esteemed journal Cell Reports, offers a beacon of hope for individuals suffering from debilitating neurological conditions and injuries.
The Intricate Dance of Neural Communication and the Loss of Regeneration
From the earliest stages of embryonic development, the human nervous system embarks on an extraordinary journey of growth and connectivity. Neurons, the fundamental building blocks of this complex network, forge intricate communication lines between the brain and the spinal cord. These signals, crucial for every voluntary and involuntary movement, are transmitted via axons. These are the long, slender projections of nerve cells that act as vital conduits, relaying messages with remarkable speed and precision to control muscle activity.
However, as the central nervous system matures, it undergoes a profound shift, largely forfeiting its innate capacity to regrow damaged axons. This developmental trade-off, while essential for establishing stable and efficient neural circuits, has historically meant that injuries to the brain or spinal cord often result in permanent functional deficits. The devastating consequences of this loss of regenerative potential are starkly evident in conditions such as paralysis, loss of motor control, and sensory impairments. Furthermore, this diminished regenerative capacity is intrinsically linked to the progression of devastating neurological diseases, including motor neurone disease (also known as ALS) and multiple sclerosis, conditions that rob individuals of their ability to move and function independently.
Engineering Miniature Human Nervous Systems: A New Frontier in Research
Building upon their prior success in creating pea-sized "brain organoids" in 2021, Dr. András Lakatos and his dedicated team at the University of Cambridge have taken a significant leap forward. These pioneering organoids, meticulously derived from human stem cells sourced from patients, accurately replicated key regions of the cerebral cortex. This initial work enabled researchers to delve into the molecular underpinnings of motor neurone disease and to explore potential preventative strategies.
The current study represents a sophisticated expansion of this research, focusing on the development of a miniature, interconnected human brain and spinal cord system. Recognizing the distinct yet intimately connected nature of these two central nervous system components, the researchers ingeniously maintained the brain and spinal cord organoids in separate physical compartments within the laboratory setting. This separation, however, did not impede the natural growth processes of the neurons. The team meticulously observed axons originating from the brain tissue extending across the intervening gap and successfully establishing functional connections with the spinal cord tissue. The resulting neural circuit proved to be sufficiently robust to elicit measurable contractions in minuscule clusters of muscle cells, providing a tangible demonstration of its functionality.
Unveiling the Developmental Window for Nerve Regrowth
A critical element of this research involved sustaining these miniature neural systems in the laboratory environment for an extended period, exceeding one year. This prolonged observation allowed the scientists to meticulously chart the developmental trajectory of axonal regeneration. Their findings revealed a crucial developmental window: up until approximately day 150 of development, a period that roughly corresponds to the mid-gestation phase of pregnancy in humans, damaged axons exhibited a significant capacity for regrowth. However, beyond this critical juncture, the neurons demonstrated a precipitous decline in their regenerative capabilities.
George Gibbons, the first author of the study and a researcher at the Department of Clinical Neurosciences at the University of Cambridge, articulated the significance of this observation: "Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow. In other words, poor regeneration is built into human neurons as they mature in the central nervous system." This statement underscores a fundamental biological principle: the inherent limitations on nerve repair are not solely a consequence of injury but are deeply embedded within the developmental programming of human neurons.
Deciphering the Genetic Switch Controlling Axon Growth
To understand the underlying mechanisms behind this developmental decline in regeneration, the research team undertook a comprehensive analysis of gene activity within the neurons responsible for connecting the brain and spinal cord. Their investigations illuminated the existence of a complex network of genes that functions akin to a biological dimmer switch. This genetic network appears to actively restrict axon growth as neurons mature and establish synaptic connections, thereby contributing to the observed loss of regenerative potential.
In a revelation that could revolutionize the treatment of nerve injuries, the researchers discovered that by strategically blocking key regulatory elements within this gene network, they could effectively restore the neurons’ ability to grow axons. This manipulation demonstrated that the inherent limitation on regeneration is not an absolute biological barrier but rather a regulated process that can be influenced and potentially reversed.
A Familiar Drug Emerges as a Potential Catalyst for Nerve Regeneration
The team’s pursuit of therapeutic interventions led them to a comprehensive search of existing drug compound databases. Their objective was to identify pharmacological agents capable of modulating the newly identified gene network. Among the numerous candidates examined, lynestrenol emerged as a particularly promising compound. Lynestrenol is a hormone-based medication currently approved for medical use in treating certain menstrual disorders and as a component of contraceptive therapies, suggesting a favorable safety profile and established regulatory pathways for its use.
When lynestrenol was administered to damaged neurons in the laboratory setting, it demonstrated a remarkable and statistically significant enhancement in axon regrowth. This finding represents a critical proof-of-concept, indicating that existing pharmacological agents might be repurposed to promote nerve regeneration.
While acknowledging that factors such as scar tissue formation and inflammation can impede nerve repair following injury, the Cambridge scientists emphasized the paramount importance of understanding the neuron-specific biological mechanisms that limit regeneration. Previous research has indicated that younger neurons possess a greater ability to navigate and grow through environments that would typically inhibit repair at injury sites. This new study provides a detailed molecular explanation for why this is the case.
Senior author Dr. András Lakatos, who spearheaded this pivotal research at the Department of Clinical Neurosciences, highlighted the profound implications of their findings: "When the brain and spinal cord are damaged, the nerve fibers that carry movement signals from the brain to the spinal cord rarely grow back. That’s why paralysis is usually permanent. But we didn’t know exactly when the ability of axons to regenerate becomes limited. Our model provides a good indication that this block happens during development, and it can still be reversed after this point."
He further elaborated on the therapeutic potential: "Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable."
The Ascendancy of Human Organoids in Biomedical Research
The groundbreaking advancements in this study underscore the rapidly increasing value of organoid technology in unraveling the complexities of human biology and disease. While animal models, such as mice and rats, have historically been indispensable tools in scientific inquiry, inherent biological differences between species can limit their accuracy in fully recapitulating human nervous system function.
Human stem cell-derived organoids, such as those developed by the Cambridge team, offer a more faithful representation of human biology. This fidelity helps to bridge the critical gap between findings in animal experiments and the actual outcomes observed in human patients. By studying human cells in a human-like context, researchers can generate more translatable and clinically relevant data.
Dr. Lakatos further emphasized the significance of these models: "Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons. Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research." This statement reflects a growing ethical imperative within the scientific community to minimize animal testing while simultaneously advancing the frontiers of human health research.
The University of Cambridge is at the forefront of leveraging organoid technology for a diverse array of medical investigations. These efforts span a broad spectrum, including pioneering work on repairing damaged livers, investigating the complexities of Crohn’s disease in pediatric populations, and studying the earliest, most delicate stages of human pregnancy.
The vital research underpinning this groundbreaking discovery was generously funded by UK Research and Innovation (UKRI) through the Medical Research Council and the Spinal Research charity, organizations dedicated to advancing medical science and improving the lives of those affected by spinal cord injuries. This collaborative effort exemplifies the power of interdisciplinary funding and partnership in driving transformative scientific progress.
